INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of today, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients. These formulary placements will provide access to INPEFA for Express Scripts commercial and Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.
- As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023
THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of today, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients. - These formulary placements will provide access to INPEFA for Express Scripts commercial and Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.
- “We continue to make progress in establishing access and reimbursement for INPEFA and are pleased by the Express Scripts decision announced today,” said Lonnel Coats, Lexicon’s chief executive officer.
- INPEFA is currently commercially available in the U.S.